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The purpose of this study is (1) to evaluate skeletal muscle magnesium (Mg) and potassium (K) during treatment with cisplatin; (2) to
evaluate the predictive value of plasma (P)-Mg for intracellular Mg during cisplatin treatment; and (3) to evaluate whether changes in
intracellular K influence skeletal muscle Na,K-ATPase. In all, 65 patients had a needle muscle biopsy obtained before and 26 patients
both before and after cisplatin treatment. Biopsies were analysed for Mg, K, and Na,K-ATPase concentrations, and P-Mg and P-K
determined. Treatment with a total dose of E500mg (270mgm
 2 surface area) cisplatin over 80 days was associated with
reductions in muscle [Mg] (95% CI) (8.95 (8.23–9.63) to 7.76 (7.34–8.18)mmolg
 1 wet wt. (Po0.01), and muscle [K] (90.81
(83.29–98.34) to 82.87 (78.74–87.00)mmolg
 1 wet wt. (Po0.05), as well as in P-Mg 0.82 (0.80–0.85) to 0.68 (0.64–
0.73)mmoll
 1 (Po0.01 but not in P-K (4.0 (3.8–4.1) vs 3.8 (3.7–4.0)mmoll
 1). No simple correlations were observed between P-
Mg and muscle [Mg], or between P-K and muscle [K], either before (n¼65) or after (n¼26) treatment with cisplatin. The changes in
[Mg] and [K] were not associated with changes in the muscle Na,K-ATPase concentration. Following treatment with cisplatin, an
E15% decline in P-Mg was accompanied by an E15% loss of muscle [Mg], as well as an E10% reduction of muscle [K] and fatigue
and muscle weakness previously ascribed to hypomagnesaemia may therefore also be well explained by muscle K depletion observed
despite normal levels of P-K. There was no correlation between P-Mg and SM-Mg or between P-K and SM-K. Thus, P-Mg and P-K are
not reliable indicators for Mg and K depletion during treatment with cisplatin. However, the majority of patients will present Mg and K
depletion after cisplatin therapy and of these only very few patients will present a low P-Mg or P-K. Therefore, routine
supplementation should be considered in all patients receiving cisplatin.
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Cisplatin is one of the most important anticancer agents for solid
tumours. Nephrotoxicity of cisplatin may result in increased
magnesium (Mg) excretion (Mavichak et al, 1985; Stewart et al,
1985; Ariceta et al, 1997), even before renal function becomes
affected (Daugaard et al, 1988). The lack of clear-cut symptoms in
most patients with even profoundly reduced levels of plasma (P)-
Mg has left it uncertain whether Mg substitution should be
instituted when the value is low. Fatigue and muscle weakness are
generally ascribed to hypomagnesaemia, although these symptoms
can be found in many patients receiving noncisplatin containing
chemotherapy as well. More feared, but rarely documented,
symptoms associated with hypomagnesaemia are Torsade des
pointes ventricular arrhythmia and muscular tetanus (Lajer and
Daugaard, 1999).
Since only 0.3% of body Mg is present in the plasma and less
than 1% is located in the extracellular space (Rude, 1993), the
effect of cisplatin on the major but less-accessible Mg stores, or the
relationship between P-Mg and these stores, during treatment with
cisplatin remains unknown. Skeletal muscles account for E30% of
body Mg, and since it is readily exchangeable, it is considered an
important reservoir (Elin, 1987). Since Mg and potassium (K)
concentrations correlate within skeletal muscles (Dorup et al,
1988b), the pathophysiology aspects of K metabolism become
important if Mg depletion is suspected. K depletion is associated
with a downregulation of Na,K-ATPase, which could explain
fatigue and muscle weakness in cisplatin-treated patients.
The purpose of this study was (1) to evaluate skeletal muscle
[Mg] and [K] during treatment with cisplatin; (2) to evaluate the
predictive value of P-Mg for intracellular [Mg] depletion during
cisplatin treatment; and (3) to evaluate whether potential changes
in K metabolism influence skeletal muscle Na,K-ATPase.
PATIENTS AND METHODS
A total of 128 patients scheduled to receive cisplatin-based
chemotherapy were asked to enter the study and 68 patients
accepted to participate. The study was approved by The
Copenhagen Ethics Committee (KF 01-092/99), and was in
accordance with Helsinki declaration II.
Muscle biopsies were planned before and following treatment.
Depending on the treatment protocol, patients received 100mg
cisplatin intravenous (i.v.)m
 2 body surface area once every
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l4 weeks (non-small-cell lung cancer (NSCLC)), 20mg cisplatin
i.v.m
 2 every day for 5 consecutive days every 3 weeks (testicular
cancer), or 40mg cisplatin i.v.m
 2 once a week for 6 weeks (cervix
cancer). The average follow-up time from the start of treatment
until the second biopsy was 12 weeks, and the average time from
the last dose of cisplatin to the second biopsy was 4 weeks. All
patients had performance status 42 according to the WHO
criteria.
Patients with diabetes or thyroid/parathyroid diseases were
excluded from the study to avoid the possible specific effects on
Mg and K metabolism. No patient received thiazide diuretics, but a
maximum of 40mg of loop diuretics was administered every third/
fourth week in connection with hydration therapy. No standard
Mg administration was given, but three patients developed a P-Mg
below 0.40mmoll
 1 once during the follow-up, and in these
patients Mg was supplemented as a single i.v. infusion of 1000ml
isotonic glucose containing 50mmol MgCl2. No K substitution was
administered.
Patients received a mean cumulative prednisolone dose of
600mg (range 150–900mg) to reduce nausea, and standard
intravenous hydration therapy consisted of 4–5l of NaCl/
glucose/mannitol per day on which cisplatin was administered.
The characteristics of the 65 patients who had successful
pretherapy biopsy are presented in Table 1. The reasons for
unavailability of both a pre- and post-therapy muscle biopsy
(n¼39) were patients declining from a second biopsy (n¼15),
logistic problems (n¼6), death of patients (n¼7), progression of
disease where taking a second biopsy was found unethical (n¼5),
pretherapy biopsy (n¼3) or post-therapy biopsy unsuitable for
analysis (n¼3). Unsuitable biopsies were biopsies too small for
measurements to be made.
Characteristics of the 26 patients in whom paired samples were
available are presented in Table 1. This group formed the basis of
all analysis related to changes before and after chemotherapy.
Glomerular filtration rate measured as
51Cr-EDTA clearance was
reduced by 19% (Po0.01) after treatment, but no significant
change in weight was observed.
In addition, it was decided at the start of the study to include
patients, who could, for logistical reasons, not be included before
therapy, with a single biopsy after therapy if they demonstrated
hypomagnesaemia. This was done to obtain patients with P-Mg
values in the lower range, thereby allowing a stronger testing for a
possible correlation between P and muscle values within this
range. Five such patients were included, and their demographic
data were in accordance with those of the 26 patients depicted in
Table 1.
P-Mg and K
Blood samples for P-Mg and P-K were collected from a cubital
vein. P-Mg was measured by the colorimetric end point method
with xylidyl blue and buffer/EGTA using Roche/Hitachi 717
(Roche Diagnostics, Mannheim, Germany). P-K was measured by
potentiometry (ion-selective electrodes) with valinomycin as ion-
specific material using the same apparatus.
Muscle biopsies
Biopsies of 20–30mg wet wt. were obtained from the lateral vastus
muscle, using a Bergstro ¨m needle following local anesthesy of the
skin, subcutis, and fascia (Lidocaine 1%) (Bergstrom, 1979). The
biopsy was immediately dissected free of visible fat and connective
tissue, divided and placed in sealed preweighted plastic tubes, and
frozen at  801C until measurements of K, Mg, and
3H-ouabain-
binding sites. Measurements on specimens obtained from the same
individual before and after cisplatin therapy were simultaneously
performed.
In undersized muscle samples, measurements of Mg and K were
given priority over
3H-ouabain binding.
Skeletal muscle Mg and K
Skeletal muscle Mg (SM-Mg) content was measured in duplicate by
atomic absorption (AAnalyst 100; Perkin-Elmer, Norwalk, CT,
USA) at 285.2nm (Dorup et al, 1988a; Bundgaard and Kjeldsen,
2002). The samples were dissolved in 1ml of 30% H2O2, and the
suspension was maintained at 901C for 12h to allow complete
evaporation. After addition of 2ml of trichloroacetic acid (TCA;
5% wtv
 1), 0.5ml of the solution was used for atomic absorption
after final addition of a further 0.5ml of 5% TCA and 1.5ml of
redistilled water. Skeletal muscle K (SM-K) content was measured
by flame photometry with an FLM 3 (Radiometer, Copenhagen,
Denmark) with lithium as an internal standard using a solution as
used for atomic absorption, except that 1.5ml of redistilled water
was substituted by 5mmoll
 1 LiCl.
3H-ouabain binding
3H-ouabain binding in intact samples was performed as previously
described (Kjeldsen, 1986; Bundgaard and Kjeldsen, 2002).
Statistics
Values are means with 95% confidence intervals (CI) or median
values with 25 and 75 percentiles as indicated. Calculations were
performed using SPSS statistical software (SPSS Inc., Chicago, IL,
USA). Differences in means between paired observations were
calculated using paired t-test, except for the ouabain-binding site
concentration where the sign test (nonparametric) was applied due
to asymmetry in the difference between pairs. Correlations were
evaluated using Pearson’s test or, in case of non-normal
distribution of data, the Spearman test. Linear regression analysis
Table 1 Clinical characteristics of patients
Before chemotherapy
Group with biopsies before: after
chemotherapy
Number of patients 65 26
Mean age in years (95% CI) 54 (51–57) 50 (45–55)
Male:female ratio 46: 19 16: 10
Mean interval between biopsies (95% CI) — 80 (73–89)
Cancer location
141:
216:
35:
41:
51:
61
117:
27:
32
Mean weight before:after treatment in kg (95% CI) — 73 (66–79): 72 (65–78), P¼0.17
Mean
51Cr-EDTA clearance before:after treatment (ml(min.x1.73m2)
 1) (95% CI) — 91 (83–99): 74 (66–82), Po0.01
Mean cumulated cisplatin dose (mg) at the time of second biopsy (95% CI) — 503 (435–572)
Mean cumulated cisplatin dosem
 2 (mg) at the time of second biopsy (95% CI) — 270 (236–304)
95% Confidence interval (CI) appears in brackets where indicated.
1Non-small-cell lung cancer;
2c. testis;
3c. uterine cervix;
4bladder cancer;
5unknown primary tumour;
6mesothelioma.
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with 95% mean prediction interval are shown. P-values o0.05
were considered statistically significant.
RESULTS
In the 65 patients measured before cisplatin treatment (Table 1), P-
Mg was 0.82 (0.80–0.84)mmoll
 1, P-K 4.0 (3.9–4.1)mmoll
 1,
SM-Mg 8.95 (8.54–9.36)mmolg
 1 wet wt., and SM-K 94.77 (90.44–
99.11)mmolg
 1 wet wt.
In the 26 patients with biopsies available before and after
cisplatin treatment (Table 1), P-Mg fell from 0.82 (0.80–0.85) to
0.68 (0.64–0.73)mmoll
 1 (Po0.01, mean difference 0.14 (0.09–
0.19)); SM-Mg from 8.95 (8.23–9.63) to 7.76 (7.34–8.18)mmolg
 1
wet wt. (Po0.01, mean difference 1.19 (0.39–1.98)) and SM-K
from 90.81 (83.29–98.34) to 82.87 (78.74–87.00)mmolg
 1 wet wt.
(Po0.05, mean difference 7.94 (0.5–15.39), where as P-K did not
change significantly (4.0 (3.8–4.1) to 3.8 (3.7–4.0)mmoll
 1)
(Figure 1, n¼26). Median values (25th and 75th percentiles) for
3H-ouabain-binding site concentration were also similar before
and after treatment (263 (238–294) vs 266 (247–289)pmolg
 1 wet
wt.). The fraction of patients low in both P-Mg and SM-Mg
increased from 11 to 41% following treatment with cisplatin. Using
the lower CI from pretherapy values as reference, 58% of the
patients were Mg depleted after treatment and out of these only
one out of three presented with low P-Mg. Equally, 58% were K
depleted and only 13% of these presented a low P-K.
No significant association was observed between P-Mg and SM-
Mg either before (n¼65, R
2¼0.00) or after (n¼26, R
2¼0.00)
treatment with cisplatin (Figure 2, n¼65 (A) and 26 (B)).
Subgroup analysis of patients with low P-Mg (o0.67mmoll
 1)
following chemotherapy also showed no association between P-Mg
and SM-Mg (n¼10, R
2¼0.26). The same result was obtained if the
analysis was carried out with the addition of the five patients
included with hypomagnesaemia and the three patients in whom
only a post-therapy biopsy was available, thereby increasing the
number of patients with P-Mg o0.67mmoll
 1 (n¼16, R
2¼0.02).
Likewise, there was no significant association between changes
in P-Mg and that in SM-Mg (n¼26, R
2¼0.01), and there was no
significant association between P-Mg and P-K before treatment
with cisplatin, but such an association was observed after
treatment (R
2¼0.55, Po0.01); (Figure 3, n¼26). An association
was also observed between SM-Mg and SM-K both before (n¼65,
R
2¼0.76, Po0.01) and after (n¼26, R
2¼0.70, Po0.01) treatment
with cisplatin, as was a correlation between the change in SM-Mg
and that in SM-K (R
2¼0.79, Po0.001; Figure 4A and B, n¼65 and
26, respectively, and Figure 5, n¼26). No association was observed
between P-K and SM-K either before or after treatment, and
equally there was no association between SM-K and skeletal
muscle
3H-ouabain-binding site concentration either before or
after treatment. Neither changed renal function, cumulated
cisplatin dose nor age correlated to the observed changes in P-
Mg, SM-Mg or SM-K.
DISCUSSION
The concentrations of Mg, K and Na,K-ATPase observed before
chemotherapy were in accordance with earlier studies, and
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when WHO performance status is better than 2 (Elin, 1987;
Clausen, 1998). P-Mg was below the lower reference level after
therapy in 38% of the patients and a novel observation was that the
decrease in P-Mg was accompanied by an E15% loss of muscle Mg
and E10% loss of muscle K; mean loss 1.2 and 8.0mmolkg
 1 wet
wt. of skeletal muscle, respectively. If this observation represents
all skeletal muscles (E40% of the total body wt.), it would mean an
average loss of E35mmol of Mg and E225mmol of K for a
patient with a body weight of 70kg, after administration of a
cumulated dose of 500mg cisplatin. Seven patients had a loss of as
much as E25% of their Mg stores and three patients approached a
25% loss of their K stores. Since there was no simple correlation
between P-values and the corresponding intracellular values, these
severe losses would in clinical practice remain undiagnosed.
The observed depletion of skeletal muscle K during treatment
with cisplatin was not suspected since a decline in P-K was not
observed. The finding suggests that P-K is adjusted at the expense
of intracellular stores during treatment with cisplatin. The K
depletion questions whether K substitution is in demand in these
patients or whether the K depletion can be expected to resolve
following a normalisation in Mg stores. Furthermore, fatigue and
muscular weakness ascribed to hypomagnesaemia may also be well
explained by K depletion. After treatment with cisplatin, an
association between Mg and K in plasma was observed, but this
association was not present prior to therapy. This observation may
be caused by a larger span of values after treatment, but could also
indicate an association in the regulation of Mg and K in plasma
under the present conditions.
Despite a decrease in skeletal muscle K, the Na,K-ATPase
concentration was normal after cisplatin treatment. This is
contrary to what was expected (Dorup et al, 1988b; Clausen,
1998), and may be caused by prednisolone administered as
antiemetic to cisplatin-treated patients, since it reportedly
upregulates the skeletal muscle Na,K-ATPase concentration
(Thompson et al, 2001). Thus, prednisolone may prevent K
depletion in cisplatin treatment from reducing muscle cell K
reuptake capacity further. If hypokalaemia does develop in these
patients, the potential for K uptake into skeletal muscle may
therefore be high. This may aggravate hypokalaemia. Hypokalae-
mia in these patients could therefore be a more serious problem.
On the other hand, Mg depletion may cause a functional reduction
in Na,K-ATPase activity (Skou, 1965; Kjeldsen and Norgaard,
1987), which then induces depletion of K.
Treatment of hypomagnesaemia related to treatment with
cisplatin has been directed towards normalisation of P-Mg with
the secondary intention to restore total body Mg (Macaulay et al,
1982; Vokes et al, 1990; Evans et al, 1995). However, P-Mg is
evidently not a reliable indicator of Mg depletion during cisplatin
chemotherapy, and neither can Mg substitution be guided by this
parameter alone. These arguments relate also to K. The approach
towards substitution of the observed losses is therefore compli-
cated, and it is not possible to develop simple guidelines for Mg or
K substitution during treatment with cisplatin. Furthermore, it
remains unknown whether Mg and K substitution is effective in
increasing body Mg and K stores during cisplatin treatment,
especially in the presence of a cisplatin-induced renal reabsorption
defect.
In conclusion, cisplatin treatment caused significant Mg and K
depletion in the majority of patients and, in most patients, this
depletion was observed despite normal corresponding P values.
Therefore, due to our inability to monitor these electrolytes during
treatment, it should be considered whether routine Mg and K
supplementation should be implemented in these patients from the
start of treatment.
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